Additional prespecified endpoint,
not controlled for multiplicity.
*Bio-naïve defined as without prior biologic failure and includes patients who had previous exposure to biologics but did not experience treatment failure.
†Bio-failure refers to prior treatment failure to at least 1 biologic therapy.
Histologic-endoscopic mucosal healing: ESS of 0 or 1 without friability and a Geboes score of ≤3.1.1,2
ESS: endoscopic subscore; QD: once daily.
REFERENCES
- RINVOQ Summary of Product Characteristics.
- Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128.